Alexander Rühle
@ruehlealex.bsky.social
MD MHBA | Radiation Oncologist and Clinician Scientist |
Dedicated to advancing head-and-neck cancer care |
Fascinated by exploring the interplay between radiotherapy and the tumor microenvironment, with a focus on tumor hypoxia
Dedicated to advancing head-and-neck cancer care |
Fascinated by exploring the interplay between radiotherapy and the tumor microenvironment, with a focus on tumor hypoxia
The EORTC's PROLoNG phase III trial, initiated by P. Balermpas, is going to evaluate the combination of pembrolizumab + SBRT for oligometastatic HNSCC. Stay tuned!
January 5, 2025 at 3:20 PM
The EORTC's PROLoNG phase III trial, initiated by P. Balermpas, is going to evaluate the combination of pembrolizumab + SBRT for oligometastatic HNSCC. Stay tuned!
💡 Key Highlights:
➡️ 16 centers from 🇩🇪 🇦🇹 🇨🇭
➡️ 178 pts w/ oligometastatic HNSCC receiving SBRT of 284 lung mets
➡️ 5.5% 1-year cumulative incidence of local failures
➡️ BED ≥100 Gy associated with fewer local failures (sHR, 0.17; p=.006)
➡️ Median OS and PFS were 33 months and 9 months, respectively
➡️ 16 centers from 🇩🇪 🇦🇹 🇨🇭
➡️ 178 pts w/ oligometastatic HNSCC receiving SBRT of 284 lung mets
➡️ 5.5% 1-year cumulative incidence of local failures
➡️ BED ≥100 Gy associated with fewer local failures (sHR, 0.17; p=.006)
➡️ Median OS and PFS were 33 months and 9 months, respectively
January 5, 2025 at 3:17 PM
💡 Key Highlights:
➡️ 16 centers from 🇩🇪 🇦🇹 🇨🇭
➡️ 178 pts w/ oligometastatic HNSCC receiving SBRT of 284 lung mets
➡️ 5.5% 1-year cumulative incidence of local failures
➡️ BED ≥100 Gy associated with fewer local failures (sHR, 0.17; p=.006)
➡️ Median OS and PFS were 33 months and 9 months, respectively
➡️ 16 centers from 🇩🇪 🇦🇹 🇨🇭
➡️ 178 pts w/ oligometastatic HNSCC receiving SBRT of 284 lung mets
➡️ 5.5% 1-year cumulative incidence of local failures
➡️ BED ≥100 Gy associated with fewer local failures (sHR, 0.17; p=.006)
➡️ Median OS and PFS were 33 months and 9 months, respectively